The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Platinum-based drugs: past, present and future
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
A family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751
The status of platinum anticancer drugs in the clinic and in clinical trials
Wheate, N. J., Walker, S., Craig, G. E., & Oun, R. (2010) · Dalton Transactions · doi:10.1039/c0dt00292e · Cited by 1,634
Immunogenic death of colon cancer cells treated with oxaliplatin
Tesniere, A., Schlemmer, F., Boige, V, Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., et al. (2010) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,173
Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect
Maeda, H., Bharate, G. Y., & Daruwalla, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.11.010 · Cited by 1,168
Bhirde, A. A., Patel, V., Gavard, J., Zhang, G., Sousa, A. A., Masedunskas, A., Leapman, R. D., Weigert, R., Gutkind, J. S., & Rusling, J. F. (2009) · ACS Nano · doi:10.1021/nn800551s · Cited by 853
Antitumour metal compounds: more than theme and variations
Jakupec, M. A., Galanski, M. S., Arion, V. B., Hartinger, C. G., & Keppler, B. K. (2008) · Dalton Transactions · doi:10.1039/b712656p · Cited by 850
Takahara, P. M., Rosenzweig, A. C., Frederick, C. A., & Lippard, S. J. (1995) · Nature · doi:10.1038/377649a0 · Cited by 769
Lebwohl, D., & Canetta, R. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00224-x · Cited by 754
Mechanisms of resistance to cisplatin and carboplatin
Stewart, D. J. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.02.001 · Cited by 631
Feazell, R. P., Nakayama-Ratchford, N., Dai, H., & Lippard, S. J. (2007) · Journal of the American Chemical Society · doi:10.1021/ja073231f · Cited by 616
Preclinical and clinical studies of anticancer agent‐incorporating polymer micelles
Matsumura, Y., & Kataoka, K. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01103.x · Cited by 501
Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II
Calvert, A. H., Harland, S. J., Newell, D. R., Siddik, Z. H., Jones, A. C., McElwain, T. J., Raju, S., Wiltshaw, E., Smith, I. E., Baker, J. M., et al. (1982) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00257742 · Cited by 484
Basis for Design and Development of Platinum(IV) Anticancer Complexes
Hall, M. D., Mellor, H. R., Callaghan, R., & Hambley, T. W. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070280u · Cited by 458
Scagliotti, G., Novello, S., von Pawel, J., Reck, M., Pereira, J. R., Thomas, M., Abrão Miziara, J. E., Balint, B., De Marinis, F., Keller, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.1321 · Cited by 447
Organic Cation Transporters Are Determinants of Oxaliplatin Cytotoxicity
Zhang, S., Lovejoy, K. S., Shima, J. E., Lagpacan, L. L., Shu, Y., Lapuk, A., Chen, Y., Komori, T., Gray, J. W., Chen, X., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0769 · Cited by 431
Furuta, T., Ueda, T., Aune, G. J., Sarasin, A. R., Kraemer, K. H., & Pommier, Y. G. (2002) · PubMed · Cited by 422
Dendrimer-platinate: a novel approach to cancer chemotherapy.
Malik, N., Evagorou, E. G., & Duncan, R. (1999) · PubMed · Cited by 417
Carbon Nanohorns as Anticancer Drug Carriers
Ajima, K., Yudasaka, M., Murakami, T., Maigné, A., Shiba, K., & Iijima, S. (2005) · Molecular Pharmaceutics · doi:10.1021/mp0500566 · Cited by 411
Dendrimer-platinate: a novel approach to cancer chemotherapy
Malik, N., Evagorou, E. G., & Duncan, R. (1999) · Anti-Cancer Drugs · doi:10.1097/00001813-199909000-00010 · Cited by 402
Nanocarriers for delivery of platinum anticancer drugs
Oberoi, H. S., Nukolova, N. V., Kabanov, A. V., & Bronich, T. K. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.014 · Cited by 396
Plummer, R., Wilson, R. H., Calvert, H., Boddy, A. V., Griffin, M., Sludden, J., Tilby, M. J., Eatock, M., Pearson, D. G., Ottley, C. J., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.6 · Cited by 390
What do we know about the reduction of Pt(IV) pro-drugs?
Wexselblatt, E., & Gibson, D. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2012.06.013 · Cited by 370
Medical Treatment of Advanced Testicular Cancer
Feldman, D. R. (2008) · JAMA · doi:10.1001/jama.299.6.672 · Cited by 370
Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate
Dhar, S., & Lippard, S. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912276106 · Cited by 369
Samimi, G., Safaei, R., Katano, K., Holzer, A. K., Rochdi, M., Tomioka, M., Goodman, M., & Howell, S. B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0137 · Cited by 358
Huang, J. C., Zamble, D. B., Reardon, J. T., Lippard, S. J., & Sancar, A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.22.10394 · Cited by 347
Understanding and improving platinum anticancer drugs--phenanthriplatin.
Johnstone, T. C., Park, G. Y., & Lippard, S. J. (2014) · PubMed · Cited by 337
Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance
Martinez-Balibrea, E., Martínez-Cardús, A., Ginés, A., Ruiz de Porras, V., Moutinho, C., Layos, L., Manzano, J. L., Bugés, C., Bystrup, S., Esteller, M., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0636 · Cited by 335
Holzer, A. K., Manorek, G. H., & Howell, S. B. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.022624 · Cited by 322
Ang, W. H., Khalaila, I., Allardyce, C. S., Juillerat-Jeanneret, L., & Dyson, P. J. (2005) · Journal of the American Chemical Society · doi:10.1021/ja0432618 · Cited by 314
Tumor-suppressor p53: implications for tumor development and prognosis.
Kirsch, D. G., & Kastan, M. B. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.3158 · Cited by 295
Vaisman, A., Varchenko, M., Umar, A., Kunkel, T. A., Risinger, J. I., Barrett, J. C., Hamilton, T. C., & Chaney, S. G. (1998) · PubMed · Cited by 294
Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatin
Boulikas, T. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903114168 · Cited by 276
Barnes, K. R., Kutikov, A., & Lippard, S. J. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.03.024 · Cited by 263
The state-of-play and future of platinum drugs
Apps, M. G., Choi, E. H. Y., & Wheate, N. J. (2015) · Endocrine-Related Cancer · doi:10.1530/erc-15-0237 · Cited by 256
Planells‐Cases, R., Lutter, D., Guyader, C., Gerhards, N. M., Ullrich, F., Elger, D. A., Kucukosmanoglu, A., Xu, G., Voss, F. K., Reincke, S. M., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201592409 · Cited by 256
Lovejoy, K. S., Todd, R. C., Zhang, S., McCormick, M. S., D'Aquino, J. A., Reardon, J. T., Sancar, A., Giacomini, K. M., & Lippard, S. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803441105 · Cited by 238
Targeted delivery of platinum-based anticancer complexes
Butler, J. S., & Sadler, P. J. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.01.004 · Cited by 237
Recent Developments in the Field of Anticancer Platinum Complexes
Galanski, M. S. (2006) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489206777442287 · Cited by 223
Monofunctional and Higher-Valent Platinum Anticancer Agents
Johnstone, T. C., Wilson, J. J., & Lippard, S. J. (2013) · Inorganic Chemistry · doi:10.1021/ic400538c · Cited by 223
Rademaker-Lakhai, J. M., Terret, C., Howell, S. B., Baud, C. M., de Boer, R. F., Pluim, D., Beijnen, J. H., Schellens, J. H. M., & Droz, J.-P. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0315 · Cited by 214
Cellular and molecular aspects of drugs of the future: oxaliplatin
Di Francesco, A. M., Ruggiero, A., & Riccardi, R. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/pl00012514 · Cited by 207
Ixr1, a Yeast Protein That Binds to Platinated DNA and Confers Sensitivity to Cisplatin
Brown, S. J., Kellett, P. J., & Lippard, S. J. (1993) · Science · doi:10.1126/science.8342024 · Cited by 178
Balmaña, J., Tung, N. M., Isakoff, S. J., Graña, B., Ryan, P. D., Saura, C., Lowe, E. S., Frewer, P., Winer, E., Baselga, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu187 · Cited by 177
Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells
Zisowsky, J., Koegel, S., Leyers, S., Devarakonda, K. R., Kassack, M. U., Osmak, M., & Jaehde, U. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.10.003 · Cited by 174
ProLindac™ (AP5346): A review of the development of an HPMA DACH platinum Polymer Therapeutic
Nowotnik, D. P., & Cvitkovic, E. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.06.004 · Cited by 167
Role of copper transporters in the uptake and efflux of platinum containing drugs
Safaei, R. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.07.046 · Cited by 160
Towards Antitumor Active trans‐Platinum Compounds
Aris, S. M., & Farrell, N. P. (2009) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.200801118 · Cited by 160
Chemotherapy advances in small-cell lung cancer.
Chan, B. A., & Coward, J. I. G. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2013.07.43 · Cited by 155
Yamasaki, M., Makino, T., Masuzawa, T., Kurokawa, Y., Miyata, H., Takiguchi, S., Nakajima, K., Fujiwara, Y., Matsuura, N., Mori, M., et al. (2011) · British Journal of Cancer · doi:10.1038/sj.bjc.6606071 · Cited by 153
Jodrell, D. I., Evans, T. R. J., Steward, W. P., Cameron, D., Prendiville, J., Aschele, C., Noberasco, C., Lind, M., Carmichael, J., Dobbs, N. A., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.04.032 · Cited by 153
Mutations of the p53 gene do not occur in testis cancer.
Peng, H., Hogg, D., Malkin, D. M., Bailey, D., Gallie, B. L., Bulbul, M., Jewett, M. A. S., Buchanan, J., & Goss, P. E. (1993) · PubMed · Cited by 152
DNA Interstrand Cross-links of the Novel Antitumor Trinuclear Platinum Complex BBR3464
Kašpárková, J., Zehnulová, J., Farrell, N. P., & Brabec, V. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208016200 · Cited by 147
A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer
Kim, E. S., Lu, C., Khuri, F. R., Tonda, M. E., Glisson, B. S., Liu, D., Jung, M., Hong, W. K., & Herbst, R. S. (2001) · Lung Cancer · doi:10.1016/s0169-5002(01)00278-1 · Cited by 136
Kalayda, G. V., Wagner, C. H., Buß, I., Reedijk, J., & Jaehde, U. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-175 · Cited by 120
Self-citationNakayama, K., Kanzaki, A., Terada, K., Mutoh, M., Ogawa, K., Sugiyama, T., Takenoshita, S., Itoh, K., Yaegashi, N., Miyazaki, K., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0454 · Cited by 114
Cisplatin@US-tube carbon nanocapsules for enhanced chemotherapeutic delivery
Guven, A., Rusakova, I. A., Lewis, M. T., & Wilson, L. J. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.060 · Cited by 111
Nováková, O., Kasparkova, J., Malina, J., Natile, G., & Brabec, V. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg863 · Cited by 105
Novohradský, V., Zerzánková, L., Štěpánková, J., Vrána, O., Raveendran, R., Gibson, D., Kašpárková, J., & Brabec, V. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.04.003 · Cited by 91
Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells
Kalayda, G. V., Wagner, C. H., & Jaehde, U. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2012.07.010 · Cited by 90
Self-citationCisplatin in the Treatment of Cancer
Wiltshaw, E. (1979) · Platinum Metals Review · doi:10.1595/003214079x2339098 · Cited by 84
Haririan, I. (2010) · International Journal of Nanomedicine · doi:10.2147/ijn.s8595 · Cited by 81
Zehnulová, J., Kašpárková, J., Farrell, N. P., & Brabec, V. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103118200 · Cited by 81
Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer
Michels, J., Vitale, I., Senovilla, L., Enot, D. P., Garcia, P., Lissa, D., Olaussen, K. A., Brenner, C., Soria, J., Castedo, M., et al. (2013) · Cell Cycle · doi:10.4161/cc.24034 · Cited by 78
DNA Metalating–Intercalating Hybrid Agents for the Treatment of Chemoresistant Cancers
Suryadi, J., & Bierbach, U. (2012) · Chemistry - A European Journal · doi:10.1002/chem.201202050 · Cited by 77
Transplatin Is Cytotoxic When Photoactivated: Enhanced Formation of DNA Cross-Links
Heringová, P., Woods, J. A., Mackay, F. S., Kašpárková, J., Sadler, P. J., & Brabec, V. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0606692 · Cited by 74
Anticancer Activity of Methyl-Substituted Oxaliplatin Analogs
Jungwirth, U., Xanthos, D. N., Gojo, J., Bytzek, A. K., Körner, W., Heffeter, P., Abramkin, S. A., Jakupec, M. A., Hartinger, C. G., Windberger, U. B., et al. (2012) · Molecular Pharmacology · doi:10.1124/mol.111.077321 · Cited by 72
Veal, G. J., Griffin, M. J., Price, E., Parry, A., Dick, G., Little, M., Yule, S. M., Morland, B. J., Estlin, E., Hale, J., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1723 · Cited by 69
Saha, P., Descôteaux, C., Brasseur, K., Fortin, S., Leblanc, V., Parent, S., Asselin, É., & Bérubé, G. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.12.017 · Cited by 56
Ma, E. S. F., Bates, W. D., Edmunds, A., Kèlland, L. R., Fojo, T., & Farrell, N. P. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050539d · Cited by 53
Contribution of intracellular ATP to cisplatin resistance of tumor cells
Schneider, V., Krieger, M. L., Bendas, G., Jaehde, U., & Kalayda, G. V. (2012) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-012-0960-6 · Cited by 51
Self-citationLi, H., Gao, X., Liu, R., Wang, Y., Zhang, M., Fu, Z., Mi, Y. M., Wang, Y., Yao, Z., & Gao, Q. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.07.006 · Cited by 47
Smyre, C. L., Saluta, G. R., Kute, T. E., Kucera, G. L., & Bierbach, U. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml2001888 · Cited by 47
Enhancing lipophilicity as a strategy to overcome resistance against platinum complexes?
Buß, I., Garmann, D., Galanski, M. S., Weber, G., Kalayda, G. V., Keppler, B. K., & Jaehde, U. (2011) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2011.02.005 · Cited by 44
Self-citationThemsche, C. V., Parent, S., Leblanc, V., Descôteaux, C., Simard, A.-M., Bérubé, G., & Asselin, É. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0113 · Cited by 38
Kabolizadeh, P., Ryan, J., & Farrell, N. P. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.12.016 · Cited by 37
Novello, S., Besse, B., Felip, E., Barlési, F., Mazières, J., Zalcman, G., von Pawel, J., Reck, M., Cappuzzo, F., Ferry, D., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu384 · Cited by 34
Yu, H., Zhang, J., Wu, X., Luo, Z., Wang, H., Sun, S., Peng, W. J., Qiao, J., Feng, Y., Wang, J., et al. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.28874 · Cited by 28
ERα-Targeted Therapy in Ovarian Cancer Cells by a Novel Estradiol-Platinum(II) Hybrid
Brasseur, K., Leblanc, V., Fabi, F., Parent, S., Descôteaux, C., Bérubé, G., & Asselin, É. (2013) · Endocrinology · doi:10.1210/en.2013-1083 · Cited by 25
Mlčoušková, J., Kašpárková, J., Suchánková, T., Komeda, S., & Brabec, V. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2012.04.015 · Cited by 25
Miller, K., Morant, R., Stenzl, A., ZUNA, I., & Wirth, M. P. (2015) · Urologia Internationalis · doi:10.1159/000381589 · Cited by 24
Kašpárková, J. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh896 · Cited by 23
Mlčoušková, J., Malina, J., Novohradský, V., Kašpárková, J., Komeda, S., & Brabec, V. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2012.05.014 · Cited by 22
Cited by
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
Platinum-based drugs for cancer therapy and anti-tumor strategies
Zhang, C., Xu, C., Gao, X., & Yao, Q. (2022) · Theranostics · doi:10.7150/thno.69424 · Cited by 1,018
The rediscovery of platinum-based cancer therapy
Rottenberg, S., Disler, C., & Perego, P. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00308-y · Cited by 972
Overcoming cancer chemotherapy resistance by the induction of ferroptosis
Wang, Y., Wu, X., Ren, Z., Li, Y., Zou, W., Chen, J., & Wang, H. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100916 · Cited by 361
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Metadata
- Authors
- Dilruba, S., & Kalayda, G. V.
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2016-02-17
- Volume
- 77
- Issue
- 6
- Pages
- 1103-1124
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2283420536
- Cited by
- 906
- References
- 86
- FWCI
- 30.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.